Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Intangibles CIM

Confidential Information Memorandum or CIM, a marketing document

CIM will highlight your company’s intangible assets and suggest how buyers can utilize them to grow, increase profits, or mitigate risk. Of course, buyers will do their own due diligence on your assets, and lots more, before closing the deal, so all assertions in the CIM must be reasonable. Overhyping a company can be a quick turnoff for buyers.

UPDATED 4/11/2023

1. Conduct an internal audit of your business operations to identify all intangible assets owned by or used in the business and gather appropriate supporting documentation for each asset. This has been performed on all 12 asset classes of LPBI and is summarized in an Excel sheet as well as in tabular form in our Business Plan. This is detailed for estimates as elaborated in the excel spreadsheet related to valuations. This internal audit has been conducted multiple times over the past three years and has expanded due to increased offerings of LPBI group over its existence.  This includes ebook translations into Spanish, the addition of audio podcasts, the expanded focus from LPBI 1.0 to 2.0 which included new directions into developing natural language processing capabilities, integration of our knowledge base for purposes of AI driven drug developent (development of galectin inhibitors), and real time meeting coverage including development of associated methodologies.
2. Prepare a detailed description of each item including the nature, scope and history of the asset, how it is used, its original cost, past and future economic benefits, ownership, licenses and any legal restrictions, useful life, potential threats, etc. Include references to supporting documentation. This is detailed in the associated table and excel spreadsheet and has been tabulated and reviewed by our board as well as by external advisors who have given a comparible evaluation of the content of intangible assets as well as an associated value. Therefore our estimates has been independently assessed and agreed upon by a third party, strenghtening our claim to the value of these tangible and intangibhle assets, As stated these assets are continually evaluated over the lifetime of LPBI by our board members, financial experts, and an internal expert in evaluating intangible assets. Therefore our numbers are ballpark with the current market valuation.

3. Group assets into appropriate asset classes (by type and business function) and save the supporting documents in a well-organized virtual data room. We have grouped our IP into 12 asset classes, each with tangible and intangible assets. This includes the cross vertical inducstry analysis of offerings relevant for each of these asset classes. We have identified multiple specific companies in each of these verticals who would benefit greatly from LPBI Groups Tangible AND Intangible Assets. We have been able to associate value (both tangible monetary value as well as non monetary intangible value for each of these prospective acquirers of our IP)

 

UPDATED on 4/10/2023

Let’s examine the e-Reputation of LPBI Group:

The Digital Age Gave Rise to New Definitions – New Benchmarks were born on the World Wide Web for the Intangible Asset of Firm’s Reputation: Pay a Premium for buying e-Reputation

https://pharmaceuticalintelligence.com/2019/07/31/the-digital-age-gave-rise-to-new-definitions-new-benchmarks-were-born-on-the-world-wide-web-for-the-intangible-asset-of-firms-reputation-pay-a-premium-for-buying-e-reputation/

 

How Buyers can utilized LPBI Group’s IP Asset Classes I, II, III, V is described in

Opportunities Map in the Acquisition Arena

https://pharmaceuticalintelligence.com/2019-vista/opportunities-map-in-the-acquisition-arena/

Intangible assets are non-physical assets that provide value to a business, including items such as

 

Portfolio of IP Assets

https://pharmaceuticalintelligence.com/portfolio-of-ip-assets/

 

LPBI Group’s trademarks

• No filing for trademarks

LPBI Group’s copyrights

• All content on PharmaceuticalIntelligence.com is copyrighted under Creative Common law
• The sole owner and operator is LPBI Group’s Founder: Aviva Lev-Ari, PhD, RN

LPBI Group’s patents

• Our content is not patentable, it is copyrighted

LPBI Group’s contracts

• Montero Language Services, Madrid, Spain
• Amazon.com, Kindle Direct Publishing
• WordPress.com
• LinkedIn.com

LPBI Group’s customer lists

• On 4/7/2023: Journal articles N = 6,170
• Journal Ontology has 740 categories of research in biomedical domains of knowledge
• # Views: N = 2,221,814
• IP Address of e-Readers N = 1,404,730 is stored on WordPress.com Cloud
• All subscribers to the website:  N = 9,459 on 4/7/2023

[IF @ $50 Annual Subscription fee for 5 years estimated potential revenues $2.5MM]

LPBI Group’s proprietary software

Web statistics computed at article historical levels not provided by WordPress.com needed to be fetched from the database

• https://pharmaceuticalintelligence.com/sop-web-stat/

Work flow for using NLP for medical text analysis

• https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/

Blockchain architecture

• https://pharmaceuticalintelligence.com/blockchain-transactions-network/

Synthetic biology software in drug discovery

• https://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/

Compute Projected Article Rate of Article Views

• https://pharmaceuticalintelligence.com/vision/pharmaceuticalintelligence-com-journal-projecting-the-annual-rate-of-article-views/

Summer 2023 software development for an Article Update System performed by ChatGPT with Wolfram PlugIn. Process description in

From: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Date: Friday, April 7, 2023 at 12:06 PM
To: Yash Choudhary <yashchd@iitk.ac.in>, “Madison Davis (Harvard Student)” <madisondavis@college.harvard.edu>
Subject: PROPOSAL for ChatGPT with Wolfram PlugIn for designing an UPDATING System for Journal articles in PharmaceuticalIntelligence.com

LPBI Group’s databases, designs

• Table of Contents of each e-Book

Abbreviated electronic Table of Contents (eTOCs) of each Volume in the EIGHTEEN-Volume BioMed e-Series

https://pharmaceuticalintelligence.com/2017/12/12/biomed-e-series-16-volumes-electronic-table-of-contents-of-each-volume/

• Platform for a multi authoring system hosted by WordPress.com
• Portals: HR – Knowledge Portals System (KPS), 3D BioPrinting, e-Voice Podcasting, Summer Internship Portal, AI in Genomics & Cancer, Coronavirus, Certificate One Year, Scientific NFTs,
• English-language Edition: BioMed e-Series of e-Books
• Spanish-language Edition: BioMed e-Series of e-Books

Asset Class I-X, Type, Quantity, Business Model, Protection, Transaction Type, Unique Value Proposition, Key Paying Customers, Key Stakeholders and Unique Selling Point

https://pharmaceuticalintelligence.com/2020/04/04/asset-class-i-x-type-quantity-business-model-protection-transaction-type-unique-value-proposition-key-paying-customers-key-stakeholders-and-unique-selling-point/

LPBI Group’s proprietary business processes

• Composition of methods and workflows for the content creation of scientific curations
• NLP Protocols – Medical text analysis with Machine Learning algorithms
• Drug design software application protocols
• eTOCs design for e-Books
• eProceedings – one key stroke generation of document at end of conference
• Tweet collections – template system

 

LPBI Group’s well protected trade secrets

No trade secrets

LPBI Group’s works of authorship

• Five Bilingual BioMed e-Series – 37 volumes [36 Books]

https://lnkd.in/ekWGNqA

• Press Release 

https://pharmaceuticalintelligence.com/press-releases/

Curator, Book Editor & Bilingual BioMed e-Series, Editor-in-Chief:

Aviva Lev-Ari, PhD, RN

• English-language Edition:  18 volumes in 17 books, and
• Spanish-language Edition (EDICIÓN EN ESPAÑOL): 19 volumes in 19 books

https://pharmaceuticalintelligence.com/five-bilingual-biomed-e-series/

LPBI Group’s key Experts, Authors, Writers (EAWs)

https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/

1.0 & 2.0 LPBI Group’s Team

• Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0
• Marcus Feldman, PhD, Member of the Board, Scientific Counsel: Life Sciences
• Stephen J. Williams, Member of the Board, Chief Scientific Officer, Senior Editor, PhD Pharmacology, BSc Toxicology
• Shraga Rottem M.D., D.Sc., Expert, Author, Writer & External Scientific Relations on AI in Medical Applications
• Sudipta Saha, PhD, Expert, Author, Writer, Co-Editor, Series D, Volume 2: Infectious Diseases
• Steve Henry, ESQ, Counsel-at-large
• George Gamota, ESQ, Advisor

INACTIVE 12/31/2021

• Irina Robu, PhD – 3D BioPrinting, Tissue Engineering, Biomaterials, Nanotechnology & Drug Delivery

INACTIVE 12/31/2022

• Gail S. Thornton, PhD(c), Contributing Editor, Author and Medical Writer, Marketing Communications

INACTIVE 12/31/2022

• Ofer Markman, PhD – Advisor to LPBI Group’s Founder on the Biotech Ecosystem in Israel and Domain Expert on Text Analysis with ML

Joel Shertok, PhD – Affiliation with LPBI Group: 12/22/2019 – 5/4/2021

• Joel Shertok, PhD, ex-Member of The Board, ex-Business Development and Process Designer of a Global AI-based External Relations Prospecting System for LPBI Group

Dr. Justin D. Pearlman, MD, PhD, FACC – External Scientific Relations: starting 5/12/2021

• Justin D. Pearlman, MD, PhD, FACC – Scientific Expert & Key Opinion Leader on Cardiovascular Diseases, Cardiac Imaging & Complex Diagnosis in Cardiology: Senior Editor & Author

Dr. Larry H. Bernstein, MD, FCAP – Ex CSO, Ex-Board Member, on medical leave since 12/31/2016.

LPBI Group’s strategic relationships

• Montero Language Services, Madrid, Spain
• GTO, Madrid, Spain

LPBI Group’s audit reports

All reports are auditable:

• Article views – WordPress.com
• e-Readers – WordPress.com
• Page downloads from books – Amazon.com KDP
• Royalties paid – Amazon.com KDP

LPBI Group’s credentials

See above, 1.0 & 2.0 LPBI Group’s Team

LPBI Group’s licenses

• No licenses in place

LPBI Group’s brand recognition

#1:

Equity Sharing Calculation: A Scoring System for Author’s (a) Total Articles (single author) and (b) multiple authors (c) Total Articles Views (d) Author’s Proportion of own articles views in the Top 14 Journal articles by Views and (e) External Citations (f) Influencer on Twitter

Curators: Aviva Lev-Ari, PhD, RN and Stephen J. Williams, PhD

https://pharmaceuticalintelligence.com/2022/04/11/equity-sharing-calculation-a-scoring-system-for-authors-a-total-articles-single-author-and-multiple-authorsb-total-articles-views-and-c-authors-proportion-of-own-articles-views-in/

 

#2:

See APPENDIX, Twitter Followers for

• @pharma_BI – official Twitter handle of LPBI Group
• @AVIVA1950 – official Twitter handle of LPBI Group’s Founder

The #WMIF19 Influencers via @symplur‘s #Healthcare Hashtags http://bit.ly/WMIF19 – By Mentions and By Tweets Ranked #4: @pharma_BI and #2: @AVIVA1950, respectively. Ranked #3 via NodeXL’s Betweenness Centrality http://bit.ly/2KB6cPN

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2019/04/13/the-wmif19-influencers-via-symplurs-healthcare-hashtags-http-bit-ly-wmif19-by-mentions-and-by-tweets-ranked-4-pharma_bi-and-2-aviva1950-respectively-ranked-3-via-node/

 

#3:

See Testimonials

https://pharmaceuticalintelligence.com/praising-lpbi/

 

APPENDIX

1. Analytics for e-Reputation based on LinkedIn 1st Degree Connections, +7,500 of LPBI Group’s Founder, 2012-2022: An Intangible Asset – Connections’ Position Seniority & Biotech / Pharma Focus

 

2. Mostly HONORED to be followed by [from an Excerpt of 117 Followers of the Twitter Account @AVIVA1950 from the List of 359 Followers] by the Number of their Followers on 2/24/2019

 

3. LPBI Group is mostly HONORED to be followed by [from an Excerpt of 136 Followers of the Twitter Account @pharma_BI from the List of 505 Followers] by the Number of their Followers on 3/20/2019

 

4. Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950

 

5. MEDIA organizations as Followers of @pharma_BI the Official Twitter Account of LPBI Group (136 out of 505 Followers): Number of Followers’ Followers, Institutions (I) and Individuals (Persons(P)), RED = Mostly Honored to be followed by

 

6. Excerpt of 136 Followers of @pharma_BI (from the List of 505 Followers) by the Number of their Followers on 3/20/2019

 

7. Excerpt of 117 Followers of @AVIVA1950 (from the List of 359 Followers) by the Number of their Followers

 

8. REACH – Two Handles on Twitter.com @AVIVA1950 @pharma_BI

 

9. 2013-2019, On the Medical & Scientific Bookshelf in Kindle Store: eReader Behaviors: Browsing, Page Downloads and Buying e-Books – LPBI Group’s BioMed e-Series, Royalties Payment Analysis 

 

10. Connections First Level on LinkedIn: 500 CEOs, 200 Big Pharma Professionals, 7,000 in Total: LPBI Group Founder – Aviva Lev-Ari, PhD, RN

 

11. LPBI’s Pipeline Map: A Positioning Perspectives – An Outlook to the Future from the Present

 

12. For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers] https://analytics.twitter.com/user/AVIVA1950/tweets

 

13. The Digital Age Gave Rise to New Definitions – New Benchmarks were born on the World Wide Web for the Intangible Asset of Firm’s Reputation: Pay a Premium for buying e-Reputation

 

14. e-Proceedings and Tweet Collections per Conference, 2013-2020, # Views=Downloads x $100: Real Time Coverage of 60 Events by ALA & SJW Update:Pending

 

15. Institutional versus Personal: Statistical Analysis of Two Twitter Handles – @pharma_BI (LPBI Group’s Official) and @AVIVA1950 (LPBI Group’s Founder’s Personal) – Comparative Analysis of Followers and The Followers of these two Handles’ Followers  

 

SOURCE for categories of Intangible assets

Highlight Your Company’s Intangible Assets When Selling

https://www.exitstrategiesgroup.com/blog/sell-a-business

Al Statz at 707-781-8580 or alstatz@exitstrategiesgroup.com